SCHEMBL31706010

SCHEMBL31706010

C#CCOc1ccc(C)cc1C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 3/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.38
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MAOB P27338 4/20 0.36
MAOA P21397 2/20 0.36
HPGD P15428 2/20 0.36
TSHR P16473 1/20 0.36
HTR2C P28335 2/20 0.35
HTR2B P41595 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HTR2A P28223 1/20 0.35
PDE4B Q07343 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9422399 0.87 HTT (0.49) LMNATP53HTTL3MBTL1MAOB
SCHEMBL5807071 0.83 USP2 (0.45) USP2MEN1KMT2ALMNAPTGDR2
SCHEMBL31706963 0.83 MEN1 (0.44) USP2MEN1KMT2ALMNAMAPT
SCHEMBL18544308 0.82 POLB (0.41) LMNAPTGDR2TP53MAPTMAOB
SCHEMBL31705752 0.81 GAA (0.48) MEN1KMT2AMAOBMAOA
SCHEMBL15349624 0.80 USP2 (0.47) USP2MEN1KMT2ALMNAPTGDR2
SCHEMBL460339 0.79 CYP1A2 (0.49) MEN1KMT2ALMNATP53MAPT
SCHEMBL9885324 0.79 KMT2A (0.47) USP2MEN1KMT2ALMNAPTGDR2
SCHEMBL25528508 0.79 SMN1; SMN2 (0.45) MEN1KMT2ALMNAMAPTL3MBTL1
SCHEMBL21695943 0.78 USP2 (0.43) USP2MEN1KMT2ALMNAPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025217552-A1 2-(TERT-BUTYL)-4-METHYLPHENYL APPENDED 1,4-DIAZEPANE BASED NOVEL TFEB ACTIVATING COMPOUNDS AS AUTOPHAGY MODULATORS FOR NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER'S DISEASE (AD) MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2025-10-16 WO disclosed